Table 1.

Cancer cachexia and sarcopenia and their relationships to demographics, clinical characteristics and GA impairments.

a)
Cohort Description		Cachexia (per International consensus definition
Variable	Group	n	Cachexia (%)	P-value (chi-sq)
All (n=100)	All	100	65.0
Gender (n=99)	Female	44	59.1	0.219
	Male	55	70.9
Cancer type	Upper GI	31	77.4	0.196
	Lower GI	18	61.1
	Lung	24	50.0
	GU	11	81.8
	Breast	5	40.0
	Other	11	63.6
Stage (n=91)	1	11	54.5	0.415
	2	10	70.0
	3	25	60.0
	4	45	75.6
Stage (n=91)	1–3	46	60.9	0.133
	4	45	75.6
Age (n=98)	<=75	25	68.0	0.872
	76–80	27	66.7
	81–85	30	66.7
	>=85	16	56.3
Falls (n=97)	No	61	62.3	0.476
	Yes	36	69.4
IADL (n=99)	0	33	48.5	0.017
	>=1	66	72.7
SPPB (n=89)	>=9	22	54.5	0.285
	<=8	67	67.2
GDS (n=94)	<=4	65	69.2	0.187
	>4	29	55.2
Fatigue (n=58)	No	17	58.8	0.879
	Yes	41	61.0

b)
Cohort Description		Sarcopenia (muscle loss alone)
Variable	Group	N	Sarcopenia (%)	P-value (chi-sq)
All (n=95)	All	95	57.9
Gender	Female	41	36.6	<0.001
	Male	54	74.1
Cancer type	Upper GI	31	61.3	0.425
	Lower GI	16	62.5
	Lung	23	43.5
	GU	10	80.0
	Breast	5	40.0
	Other	10	60.0
Stage (n=88)	1	10	40.0	0.132
	2	10	60.0
	3	24	45.8
	4	44	70.5
Stage (n=88)	1–3	44	47.7	0.030
	4	44	70.5
Age (n=95)	<=75	25	56.0	0.817
	76–80	25	56.0
	81–85	29	55.2
	>=85	16	68.8
Falls (n=92)	No	58	60.3	0.488
	Yes	34	52.9
IADL (n=94)	0	30	46.7	0.148
	>=1	64	62.5
SPPB (n=86)	>=9	21	52.4	0.716
	<=8	65	56.9
GDS (n=88)	<=4	62	56.5	0.951
	>4	28	57.1
Fatigue (n=57)	No	17	41.2	0.096
	Yes	40	65.0